FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1231453676> ?p ?o ?g. }

• W1231453676 endingPage "577" @default.
• W1231453676 startingPage "571" @default.
• W1231453676 abstract "Abstract The molecular approach for the analysis of leukemia associated chromosomal translocations has led to the identification of prognostic relevant subgroups. In pediatric acute lymphoblastic leukemia (ALL), the most common translocations, t(9; 22) and t(4; 11), have been associated with a poorer clinical outcome. Recently the TEL gene at chromosome 12p13 and the AML1 gene at chromosome 21q22 were found to be involved in the translocation t(12; 21)(p13; q22). By conventional cytogenetics, however, this chromosomal abnormality is barely detectable and occurs in less than 0.05% of childhood ALL. To investigate the frequency of the molecular equivalent of the t(12; 21), the TEL/AML1 gene fusion, we have undertaken a prospective screening in the running German Berlin-Frankfurt-Münster (BFM) and Italian Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) multicenter ALL therapy trials. We have analyzed 334 unselected cases of pediatric ALL patients consecutively referred over a period of 5 and 9 months, respectively. The overall incidence of the t(12; 21) in pediatric ALL is 18.9%. The 63 cases positive for the TEL/AML1 chimeric products ranged in age between 1 and 12 years, and all but one showed CD10 and pre-B immunophenotype. Interestingly, one case displayed a pre-pre–B immunophenotype. Among the B-lineage subgroup, the t(12; 21) occurs in 22.0% of the cases. Fifteen of 61 (24.6%) cases coexpressed at least two myeloid antigens (CD13, CD33, or CDw65) in more than 20% of the gated blast cells. DNA index was available for 59 of the 63 TEL/AML1 positive cases; a hyperdiploid DNA content (≥1.16) was detected in only four patients, being nonhyperdiploid in the remaining 55. Based on this prospective analysis, we retrospectively evaluated the impact of TEL/AML1 in prognosis by identifying the subset of B-lineage ALL children enrolled in the closed German ALL-BFM-90 and Italian ALL-AIEOP-91 protocols who had sufficient material for analysis. A total of 342 children were investigated for the presence of TEL/AML1 fusion gene and 99 cases (28.9%) were positive. The patients expressing the TEL/AML1 fusion mRNA appeared to have a better event-free survival (EFS) than the patients who lacked this chimeric product. Whereas three of the TEL/AML1 positive cases (3.0%) have relapsed to date, 27 patients without TEL/AML1 rearrangement (11.1%) suffered from relapse. To date, the only subset of B-lineage ALL with a favorable prognosis has been the hyperdiploid group (DNA index ≥1.16 &lt;1.6). Our findings reinforce the need to include the molecular screening of the t(12; 21) translocation within ongoing prospective ALL trials to prove definitively its prognostic impact." @default.
• W1231453676 created "2016-06-24" @default.
• W1231453676 creator A5008517987 @default.
• W1231453676 creator A5020812442 @default.
• W1231453676 creator A5032050812 @default.
• W1231453676 creator A5042645225 @default.
• W1231453676 creator A5044965982 @default.
• W1231453676 creator A5045686051 @default.
• W1231453676 creator A5051520180 @default.
• W1231453676 creator A5051981929 @default.
• W1231453676 creator A5076365826 @default.
• W1231453676 creator A5083575870 @default.
• W1231453676 creator A5085018653 @default.
• W1231453676 creator A5085469517 @default.
• W1231453676 creator A5089336179 @default.
• W1231453676 creator A5091266131 @default.
• W1231453676 date "1997-07-15" @default.
• W1231453676 modified "2023-10-16" @default.
• W1231453676 title "Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials" @default.
• W1231453676 cites W123071911 @default.
• W1231453676 cites W1731955413 @default.
• W1231453676 cites W1740534 @default.
• W1231453676 cites W1984522634 @default.
• W1231453676 cites W2022340851 @default.
• W1231453676 cites W2031096243 @default.
• W1231453676 cites W2032149567 @default.
• W1231453676 cites W2036180570 @default.
• W1231453676 cites W2056793762 @default.
• W1231453676 cites W2066119119 @default.
• W1231453676 cites W2129762592 @default.
• W1231453676 cites W2236639694 @default.
• W1231453676 cites W2259575063 @default.
• W1231453676 cites W2289456713 @default.
• W1231453676 cites W2294291334 @default.
• W1231453676 cites W2318102881 @default.
• W1231453676 cites W2328329944 @default.
• W1231453676 cites W4233117964 @default.
• W1231453676 cites W4239897690 @default.
• W1231453676 cites W4255119797 @default.
• W1231453676 cites W4294216491 @default.
• W1231453676 doi "https://doi.org/10.1182/blood.v90.2.571" @default.
• W1231453676 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9226156" @default.
• W1231453676 hasPublicationYear "1997" @default.
• W1231453676 type Work @default.
• W1231453676 sameAs 1231453676 @default.
• W1231453676 citedByCount "304" @default.
• W1231453676 countsByYear W12314536762012 @default.
• W1231453676 countsByYear W12314536762013 @default.
• W1231453676 countsByYear W12314536762014 @default.
• W1231453676 countsByYear W12314536762015 @default.
• W1231453676 countsByYear W12314536762016 @default.
• W1231453676 countsByYear W12314536762017 @default.
• W1231453676 countsByYear W12314536762018 @default.
• W1231453676 countsByYear W12314536762019 @default.
• W1231453676 countsByYear W12314536762020 @default.
• W1231453676 countsByYear W12314536762021 @default.
• W1231453676 countsByYear W12314536762022 @default.
• W1231453676 countsByYear W12314536762023 @default.
• W1231453676 crossrefType "journal-article" @default.
• W1231453676 hasAuthorship W1231453676A5008517987 @default.
• W1231453676 hasAuthorship W1231453676A5020812442 @default.
• W1231453676 hasAuthorship W1231453676A5032050812 @default.
• W1231453676 hasAuthorship W1231453676A5042645225 @default.
• W1231453676 hasAuthorship W1231453676A5044965982 @default.
• W1231453676 hasAuthorship W1231453676A5045686051 @default.
• W1231453676 hasAuthorship W1231453676A5051520180 @default.
• W1231453676 hasAuthorship W1231453676A5051981929 @default.
• W1231453676 hasAuthorship W1231453676A5076365826 @default.
• W1231453676 hasAuthorship W1231453676A5083575870 @default.
• W1231453676 hasAuthorship W1231453676A5085018653 @default.
• W1231453676 hasAuthorship W1231453676A5085469517 @default.
• W1231453676 hasAuthorship W1231453676A5089336179 @default.
• W1231453676 hasAuthorship W1231453676A5091266131 @default.
• W1231453676 hasConcept C10205521 @default.
• W1231453676 hasConcept C104317684 @default.
• W1231453676 hasConcept C111829193 @default.
• W1231453676 hasConcept C120665830 @default.
• W1231453676 hasConcept C121332964 @default.
• W1231453676 hasConcept C126322002 @default.
• W1231453676 hasConcept C138626823 @default.
• W1231453676 hasConcept C143998085 @default.
• W1231453676 hasConcept C147483822 @default.
• W1231453676 hasConcept C176290653 @default.
• W1231453676 hasConcept C196166836 @default.
• W1231453676 hasConcept C203014093 @default.
• W1231453676 hasConcept C2778274637 @default.
• W1231453676 hasConcept C2778461978 @default.
• W1231453676 hasConcept C2779823535 @default.
• W1231453676 hasConcept C2781107101 @default.
• W1231453676 hasConcept C28328180 @default.
• W1231453676 hasConcept C2909962599 @default.
• W1231453676 hasConcept C54355233 @default.
• W1231453676 hasConcept C61511704 @default.
• W1231453676 hasConcept C71924100 @default.
• W1231453676 hasConcept C86803240 @default.
• W1231453676 hasConceptScore W1231453676C10205521 @default.
• W1231453676 hasConceptScore W1231453676C104317684 @default.
• W1231453676 hasConceptScore W1231453676C111829193 @default.

• next